Gil Price

Gil Price is a Rockville, Maryland-based angel writing $25K to $100K at pre-seed and seed into pharma and biotech. He is publicly associated with MaGil IRB, an institutional review board services company, which signals deep operating exposure to clinical trial regulation, protocol design, and the practical realities of getting therapies through human studies. There is no listed LinkedIn or website, which limits public visibility, but the IRB background is a meaningful operator-angel credential for therapeutics founders. AI is not a focus, and digital health and devices are not stated verticals, so this check is narrow: it is for biotech and pharma teams who can benefit from an investor who has read thousands of protocols and consent forms. Check size and structure indicate he is a single-conviction angel, not a round-leader, useful primarily as a regulatory and clinical-operations advisor on the cap table alongside a specialist biotech seed or Series A fund. Founders most likely to convert are early therapeutics teams approaching first-in-human trials, biotech platforms with multiple INDs ahead, and any team that needs a sharp eye on trial design and regulatory pathway risk. The Mid-Atlantic and Boston biotech corridors will be easiest from a relationship and meeting standpoint. The entry path is a Crunchbase-driven referral via mutual biotech investor connections or direct outreach through MaGil IRB, framing the ask around regulatory expertise rather than pure capital and tying the round to a specific IND or clinical-trial milestone.